241 related articles for article (PubMed ID: 25047979)
61. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.
Streetly MJ; Gyertson K; Daniel Y; Zeldis JB; Kazmi M; Schey SA
Br J Haematol; 2008 Apr; 141(1):41-51. PubMed ID: 18324965
[TBL] [Abstract][Full Text] [Related]
62. Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial.
Komrokji RS; Al Ali NH; Padron E; Cogle C; Tinsley S; Sallman D; Lancet JE; Lis AF
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):251-254. PubMed ID: 30852241
[TBL] [Abstract][Full Text] [Related]
63. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.
Gupta V; Mesa RA; Deininger MW; Rivera CE; Sirhan S; Brachmann CB; Collins H; Kawashima J; Xin Y; Verstovsek S
Haematologica; 2017 Jan; 102(1):94-102. PubMed ID: 27634203
[TBL] [Abstract][Full Text] [Related]
64. Struggling with myelofibrosis-associated anemia.
Guglielmelli P; Vannucchi AM
Leuk Res; 2013 Nov; 37(11):1429-31. PubMed ID: 24011697
[No Abstract] [Full Text] [Related]
65. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.
Verstovsek S; Odenike O; Singer JW; Granston T; Al-Fayoumi S; Deeg HJ
J Hematol Oncol; 2016 Dec; 9(1):137. PubMed ID: 27931243
[TBL] [Abstract][Full Text] [Related]
66. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
[TBL] [Abstract][Full Text] [Related]
67. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
68. [Research and Applications Progress of Lenalidomide for Myelofibrosis--Review].
Fan WJ; Wu T; Chen JW; Bai H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1854-1857. PubMed ID: 30501733
[TBL] [Abstract][Full Text] [Related]
69. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis.
Quintás-Cardama A; Kantarjian H; Estrov Z; Borthakur G; Cortes J; Verstovsek S
Leuk Res; 2012 Sep; 36(9):1124-7. PubMed ID: 22475363
[TBL] [Abstract][Full Text] [Related]
70. Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents.
Visani G; Mele A; Malagola M; Isidori A; Finelli C; Piccaluga PP
Leukemia; 2003 Aug; 17(8):1669-70. PubMed ID: 12886259
[No Abstract] [Full Text] [Related]
71. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.
Lacy MQ; Hayman SR; Gertz MA; Dispenzieri A; Buadi F; Kumar S; Greipp PR; Lust JA; Russell SJ; Dingli D; Kyle RA; Fonseca R; Bergsagel PL; Roy V; Mikhael JR; Stewart AK; Laumann K; Allred JB; Mandrekar SJ; Rajkumar SV
J Clin Oncol; 2009 Oct; 27(30):5008-14. PubMed ID: 19720894
[TBL] [Abstract][Full Text] [Related]
72. Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin.
Hasselbalch HC; Clausen NT; Jensen BA
Am J Hematol; 2002 Jun; 70(2):92-9. PubMed ID: 12111781
[TBL] [Abstract][Full Text] [Related]
73. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.
Mesa RA; Camoriano JK; Geyer SM; Wu W; Kaufmann SH; Rivera CE; Erlichman C; Wright J; Pardanani A; Lasho T; Finke C; Li CY; Tefferi A
Leukemia; 2007 Sep; 21(9):1964-70. PubMed ID: 17581608
[TBL] [Abstract][Full Text] [Related]
74. Treatment considerations for primary myelofibrosis.
Biemond BJ
Neth J Med; 2010 Aug; 68(1):291-2. PubMed ID: 20739724
[No Abstract] [Full Text] [Related]
75. Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis.
Parikh SA; Kantarjian H; Schimmer A; Walsh W; Asatiani E; El-Shami K; Winton E; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):285-9. PubMed ID: 20709666
[TBL] [Abstract][Full Text] [Related]
76. A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF).
Mascarenhas J; Sandy L; Lu M; Yoon J; Petersen B; Zhang D; Ye F; Newsom C; Najfeld V; Hochman T; Goldberg JD; Hoffman R
Leuk Res; 2017 Feb; 53():13-19. PubMed ID: 27930945
[TBL] [Abstract][Full Text] [Related]
77. Chromosome 5q deletion is extremely rare in patients with myelofibrosis.
Takahashi K; Cortes J; Pierce S; Abruzzo L; Kantarjian H; Verstovsek S
Leuk Res; 2013 May; 37(5):552-5. PubMed ID: 23391517
[TBL] [Abstract][Full Text] [Related]
78. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.
Komrokji RS; Seymour JF; Roberts AW; Wadleigh M; To LB; Scherber R; Turba E; Dorr A; Zhu J; Wang L; Granston T; Campbell MS; Mesa RA
Blood; 2015 Apr; 125(17):2649-55. PubMed ID: 25762180
[TBL] [Abstract][Full Text] [Related]
79. Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes.
Raza A; Lisak L; Billmeier J; Pervaiz H; Mumtaz M; Gohar S; Wahid K; Galili N
Leuk Lymphoma; 2006 Mar; 47(3):433-40. PubMed ID: 16396766
[TBL] [Abstract][Full Text] [Related]
80. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]